People News
Agenus Inc., an immuno-onclogy (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies, announced that Manuel Hidalgo, MD, PhD has joined the company as Strategic Advisor and Paulo Moreira is now its Global Head of Clinical Operations.
Lab Connect has appointed Anthony Todd Everhart, MD, FACP as its Medical Director.
Shaolin Zhou, PhD, has been named as the new senior vice president and lab director for Bioanalytical Servies for Worldwide Clinical Trials.
Ergomed plc, has appointed Roy Ovel as its Chief Commercial Officer.
Veeva Systems announced that Tom Schwenger will join the company as president and COO in September 2019 to lead strategy, sales, and services. He currently has regional responsibility for Accenture's Northeast Products Industries Practice which includes life sciences and related industries. Previously, he led the growth of its North American Life Sciences Practice.
Michele Reed
Ashfield Medical Affairs, part of UDG Healthcare, announced Michele Reed as Vice President of Business Developmet for Ashfield Medical Information and Pharmacovigilance.
BBK Worldwide announced the promotion of David B. Fleishman to Principal.
CluePoints, a provider of Risk-Based Study Execution (RBx) and Data Quality Oversight software, has appointed SuzanneLukac as Senior Account Director and Richard Davies as VP, Solutions Expert.
Rama Kondru, PhD has been named Chief Information Officer of a new Medidata company called Acorn AI.
The WIRB-Copernicus Group (WCG) announced Jonathan Zung, PhD as Executive Vice President of its Site Divison, and David Wynes, PhD, also to its Site Division as an expert and external advisor.
Worldwide Clinical Trials has announced that Philippa Marshall, MD, BSc, FFPM has joined the company as Vice President, Scientific Solutions, focused on immune-mediated inflammatory disorders (IMID.)
Business News
Certara, a provider of model-informed drug development, regulatory science, real-world evidence and market access services, announced tha Brazil's National Health Surveillance Agency-ANVISA, Japan's Pharmaceuticals and Medical Device Agency (PMDA), and the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) are increasing their adoption of Certara's Phoenix software to evaluate drug regulatory submissions.
CluePoints also announced it is moving to larger premises in both Belgium and the United States to accommdate is growing workforce.
Sharp, a part of UDG Healthcare plc, a provider of contract packaging and clinical supplies, has received approval from the Medicines and Healthcare Product Regulatory Agency (MHRA) to begin production at its Clinical Services Center of Excellence in Rhymney, Wales.
Recognition
PARAXEL announced it has been ranked number one among global Clinical Research Organizations (CROs) for service provider leadership in Phae II/III clinical research according to a global survey of pharmaceutical and biotechnology companies by Industry Standard Research (ISR.)
West Pharmaceutial Services, a provider of solutions for injectable drug administration, announced the Company's recognition by the Philadelphia Business Journal as a 2019 Faces of Philanthropy award recipient. West received the honor for its ongoing support of Fox Chase Cancer Center.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.